Usefulness of LacdiNAc-glycosylated Prostate-specific Antigen Density for Predicting Pathological Findings of Magnetic Resonance Imaging-transrectal Ultrasound Fusion Image-guided Prostate Biopsy for the Patients With Highest Prostate Imaging Reporting and Data System Category ≥3.
Sunao ShojiTakatoshi KayaYumiko TanakaKohei UemuraTaku KusakaKumpei TakahashiSoichiro YuzurihaTatsuo KanoIzumi HanadaTatsuya UmemotoTakahiro OgawaMayura NakanoMasayoshi KawakamiMasahiro NittaMasanori HasegawaKazunobu HashidaTerumitsu HasebeTomonori KanekoJun OkadaSatomi AsaiAkira MiyajimaPublished in: The Journal of urology (2022)
LDN-PSAD would be a biomarker for detecting clinically significant prostate cancer in patients with prostate specific antigen levels ≤20 ng/mL and suspicious lesions with PI-RADS category ≥3. The use of LDN-PSAD as an adjunct to the use of prostate specific antigen levels would avoid unnecessary biopsies in patients with the highest PI-RADS category 3. Multi-institutional studies with large population are recommended.
Keyphrases
- prostate cancer
- magnetic resonance imaging
- radical prostatectomy
- ultrasound guided
- fine needle aspiration
- high resolution
- computed tomography
- benign prostatic hyperplasia
- electronic health record
- big data
- machine learning
- emergency department
- adverse drug
- case control
- data analysis
- diffusion weighted imaging
- artificial intelligence
- mass spectrometry
- contrast enhanced ultrasound
- photodynamic therapy